CBRX Profile
Columbia
Laboratories, Inc. (CBRX) is a publicly-traded biopharmaceutical
company that develops women's health and reproductive medicine
products. The company was founded in 1986 and is headquartered in
Boston, Massachusetts.
Columbia Laboratories' primary focus is
on developing products that address unmet needs in women's
reproductive health, including products for infertility, menstrual
disorders, and preterm birth. The company's products are designed to
improve the chances of successful pregnancies and reduce the risk of
premature birth.
One of the company's most significant products
is PROCHIEVE, which is a vaginal gel that contains progesterone, a
hormone that is essential for maintaining a healthy pregnancy.
PROCHIEVE is used to support women who have had recurrent pregnancy
loss and women undergoing in vitro fertilization (IVF) treatment.
In addition to its reproductive medicine products, Columbia
Laboratories also develops products that improve drug delivery,
including the CRINONE progesterone gel, which uses the company's
proprietary bioadhesive technology to deliver progesterone in a
consistent and efficient manner.
Columbia Laboratories has a
diverse portfolio of products and has partnerships with several
pharmaceutical companies, including Watson Pharmaceuticals and Merck
Serono. The company also collaborates with academic institutions and
research organizations to develop new products and technologies.
As of September 2021, the company's stock was traded on the OTC
Pink market under the symbol &";
|
